Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Renalytix Plc (RNLXY)
:RNLXY
Holding RNLXY?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.09Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Sep 03, 2019
|% Change Since: 73.33%
|Next Earnings Date:Mar 25, 2019
Earnings Call Sentiment|Neutral
The earnings call reflected a mix of positive milestones such as Medicare approval, inclusion in clinical guidelines, and operational efficiencies, against challenges like revenue decline, reduced test volumes, and financial losses. Strategic initiatives and financing efforts show promise for future growth, but immediate challenges remain.Company Guidance
During the Renalytix Q3 2024 earnings call, several key metrics and developments were discussed. The company reported revenue of $535,000 for the quarter, with 806 tests processed, of which 82% were billable, reflecting a diversification of testing locations away from a single hospital system. Operating expenses were reduced by 40% year-over-year to $6.5 million, contributing to a net loss of $7.7 million, which was a 36% improvement from the prior year. The company highlighted a 33% increase in direct-to-primary care test order rates quarter-over-quarter, driven by a newly trained sales force. Renalytix's cash position was approximately $4.7 million as of March 31, 2024, excluding recent financing proceeds. Strategic discussions are ongoing, following interest from multiple potential acquirers, with a focus on maximizing shareholder value.Medicare Approval for KidneyIntelX
Medicare contractor issued a draft local coverage determination for KidneyIntelX, expecting final coverage soon after a lengthy process, including hearings and data submissions.
Inclusion in International Guidelines
KidneyIntelX was included in the final international clinical guidelines for chronic kidney disease (KDIGO), marking a critical milestone for its adoption.
Launch of KidneyIntelX.dkd
Launched the FDA-authorized KidneyIntelX.dkd product, receiving commercial test orders with a price of $950 per test and broad insurance reimbursement.
Significant Operational Efficiency Gains
Implemented a 50% headcount reduction and an overall OpEx reduction of approximately 40% year-over-year, reducing expenses significantly from their peak.
Sales Force Performance
A newly trained sales force achieved a 33% increase in direct to primary care test order rates quarter-over-quarter.
Successful Equity Financing
Completed common stock equity financing rounds in March and April, raising $13.5 million in aggregate gross proceeds.
---
RNLXY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RNLXY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 20, 2024 | $0.15 | $0.15 | 0.00% |
| Oct 01, 2024 | $0.21 | $0.21 | 0.00% |
| May 15, 2024 | $0.66 | $0.57 | -13.64% |
| Feb 15, 2024 | $1.21 | $0.78 | -35.54% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Renalytix Plc (RNLXY) report earnings?
Renalytix Plc (RNLXY) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Renalytix Plc (RNLXY) earnings time?
Renalytix Plc (RNLXY) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RNLXY EPS forecast?
Currently, no data Available
---